Opinion statement
Neuromodulation devices are used in the treatment of medically refractory epilepsy. This has been defined as epilepsy with persistent seizures despite adequate trials of at least two anti-epileptic drugs (AEDs). In most cases of medically refractory partial epilepsy, the first choice of treatment is resective surgery if the seizure focus can be definitively localized and if surgery can be safely performed without causing intolerable neurologic deficits. Patients with medically refractory epilepsy who are not candidates for potentially curative surgery may benefit from the implantation of a neuromodulation device. While most of these devices require surgical implantation, they provide a significant added seizure reduction without typical medication side effects. Furthermore, the efficacy of these devices continues to improve over years. There are currently no head-to-head trials comparing the different neuromodulation devices but efficacy appears to be roughly similar. The choice of device therefore depends on the type of epilepsy, whether the seizure focus can be identified, and other clinical factors. Vagal Nerve Stimulation (VNS) does not require identification of the seizure focus and also carries an FDA indication for depression. While in the United States VNS is only approved for use in partial epilepsy, it is commonly used off-label to treat generalized seizures as well. VNS delivers stimulation on a scheduled basis, in response to patient activation, or in response to heart rate increases serving as a proxy for seizures. Responsive Neurostimulation (RNS) requires the identification of up to two seizure foci and delivers stimulation only in response to the detection of epileptiform activity. While it requires intracranial placement of electrodes, it allows for long-term monitoring of electrographic seizures and may be effective where VNS has not produced an optimal response. Deep brain stimulation of the anterior nucleus of the thalamus is not FDA approved at this time but is available in Europe and many other parts of the world. While it also carries an indication only for partial epilepsy, it does not require identification of the seizure focus and may be particularly helpful for temporal lobe epilepsy. It also appears effective in cases where VNS has not been sufficiently helpful. The Trigeminal Nerve Stimulation (TNS) system is another treatment modality which is not yet FDA approved but is available in Europe and other countries. Its mechanism of action is similar to the VNS system and it also appears to have anti-depression effects in addition to anti-epileptic benefits. However, the most compelling feature of TNS is that it is not implanted but rather applied to the skin with transdermal electrodes, typically at night.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology. 2007;68:326–37. doi:10.1212/01.wnl.0000252807.38124.a3.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–9. doi:10.1056/NEJM200002033420503.
Surges R, Sander JW. Sudden unexpected death in epilepsy: mechanisms, prevalence, and prevention. Curr Opin Neurol. 2012;25(2):201–7. doi:10.1097/WCO.0b013e3283506714.
Wiebe S, Blume WT, Girvin JP, Eliasziw M, Group E and E of S for TLES. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345:311–8. doi:10.1056/NEJM200108023450501.
Engel J, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012;307:922–30. doi:10.1001/jama.2012.220. Recent study demonstrating the need for early identification of medically refractory epilepsy and surgical intervention.
Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51(5):899–908. doi:10.1111/j.1528-1167.2010.02536.x.
Morrell MJ. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology. 2011;77(13):1295–304. doi:10.1212/WNL.0b013e3182302056.
Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. vol 51. 1998. doi: 10.1212/WNL.51.1.48.
Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology. 2015;84:810–7. doi:10.1212/WNL.0000000000001280. The most recent long-term follow-up update of the responsive neurostimulation cohort from the feasibility and pivotal trials.
Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology. 2015;84:1017–25. doi:10.1212/WNL.0000000000001334. The most recent long-term follow-up update of the stimulation of the anterior nucleus of the thalamus (SANTE) cohort from the Phase III trial.
Elliott RE, Morsi A, Kalhorn SP, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav. 2011;20(1):57–63. doi:10.1016/j.yebeh.2010.10.017.
Meador KJ, Kapur R, Loring DW, Kanner AM, Morrell MJ. Quality of life and mood in patients with medically intractable epilepsy treated with targeted responsive neurostimulation. Epilepsy Behav. 2015;45:242–7. doi:10.1016/j.yebeh.2015.01.012. Study showing improvement in quality of life measures in patients undergoing responsive neurostimulation.
Morris GL, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: Report of the guideline development subcommittee of the american academy of neurology. Neurology. 2013;81(16):1453–9. doi:10.1212/WNL.0b013e3182a393d1. Review providing evidence-based guidelines in the use of VNS.
Heck C, Helmers SL, DeGiorgio CM. Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use. Neurology. 2002;59(6 Suppl 4):S31–7. doi:10.1212/WNL.59.6_suppl_4.S31.
Morris GL, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. the Vagus Nerve Stimulation Study Group E01-E05. Neurology. 1999;53(8):1731–5.
Elliott RE, Morsi A, Tanweer O, et al. Efficacy of vagus nerve stimulation over time: review of 65 consecutive patients with treatment-resistant epilepsy treated with VNS >10 years. Epilepsy Behav. 2011;20(3):478–83. doi:10.1016/j.yebeh.2010.12.042.
Soss J, Heck C, Murray D, et al. A prospective long-term study of external trigeminal nerve stimulation for drug-resistant epilepsy. Epilepsy Behav. 2015;42:44–7. doi:10.1016/j.yebeh.2014.10.029. Prospective long-term study of trigeminal nerve stimulation consiting of patient who completed Phase II trial.
Compliance with Ethics Guidelines
Conflict of Interest
George Nune reports research support without any direct financial benefits from Neuropace Inc. and Cyberonics Inc. during the conduct of the study.
Christopher DeGiorgio was previously an employee of Neurosigma Inc. and co-owns relevant patents from which he has received royalties.
Christianne Heck reports non-financial support and other research support from Neuropace Inc and other support from NeuroSigma during the conduct of the study.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Epilepsy
Rights and permissions
About this article
Cite this article
Nune, G., DeGiorgio, C. & Heck, C. Neuromodulation in the Treatment of Epilepsy. Curr Treat Options Neurol 17, 43 (2015). https://doi.org/10.1007/s11940-015-0375-0
Published:
DOI: https://doi.org/10.1007/s11940-015-0375-0